No Detail Found!

Long-term Outcomes of Paclitaxel-eluting Versus Sirolimus-eluting Stent for Percutaneous Coronary Intervention: a Meta-analysis.

Author(s)
Jie Kong Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China
Peng Liu Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China
Xueqiang Fan Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China
Jianyan Wen Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China
Jianbin Zhang Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China
Yanan Zhen Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China
Jinyong Li Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China
Yiyao Cui Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, ChinaSurgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China-100029, China
Xia Zheng Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, ChinaSurgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China-100029, China
Zhidong Ye Department of Vascular Surgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, ChinaSurgery, China-Japan Friendship Hospital, Graduate School of Peking Union Medical College, Beijing, China-100029, China
Abstract
The relative long-term efficacy and safety of sirolimus-eluting stents (SES) compared with paclitaxel-eluting stents (PES) in multiple comparative studies remains controversial. This report evaluates 29 randomized trials with 18,379 patients in whom long-term (more than 1 year) outcomes were evaluated. The primary outcomes were target lesion revascularization (TLR) and the secondary end points were death, cardiac death, myocardial infarction (MI), major adverse cardiac events (MACEs), target vessel revascularization (TVR) and stent thrombosis (ST). In comparison with PES, SES significantly reduced the long-term risk of TLR (RR=0.68; 95% CI=0.57 to 0.80, p<0.001), TVR (RR=0.69; 95% CI= 0.60 to 0.79, p<0.001) and MACE (RR=0.82; 95% CI= 0.77 to 0.88, p<0.001), while there were no significant difference with respect to death, cardiac death, MI and ST between the two groups. SES performance was significantly better for reducing the former three outcomes and comparable for the majority of the secondary end points when compared against PES.
Publication Details
Page(s) 432-439
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 7, Year: 2017

Request the full text from PASTIC

References
ByrneRA,SarafoffN,KastratiA,SchomigA, 2009.Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment,Drug Saf 32 749 -70
De LucaG,DirksenMT,SpauldingC, 2012.Drug-eluting vs baremetal stents in primary angioplasty: a pooled patient-level metaanalysis of randomized trials,Arch Intern Med 172 611 -21
StoneGW,EllisSG,CoxDA, 2004.A polymer-based, paclitaxeleluting stent in patients with coronary artery disease,N Engl J Med 350 221 -31
ByrneRA,JonerM,KastratiA, 2009.Polymer coatings and delayed arterial healing following drug-eluting stent implantation,Minerva Cardioangiol 57 567 -84
FinnAV,NakazawaG,KolodgieFD,VirmaniR, 2009.Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?,JACC Cardiovasc Interv 2 300 -2
FinnAV,NakazawaG,JonerM., 2007.Vascular responses to drug eluting stents: importance of delayed healing,Arterioscler Thromb Vasc Biol 27 1500 -10
KastratiA,MehilliJ,PacheJ, 2007.Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents,N Engl J Med 356 1030 -9
MorenoR,FernandezC,HernandezR, 2005.Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies,J Am Coll Cardiol 45 954 -9
WesselyR,SchomigA,KastratiA, 2006.Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different,J Am Coll Cardiol 47 708 -14
KastratiA,MehilliJ,von BeckerathN., 2005.Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial,JAMA 293 165 -71
MehilliJ,DibraA,KastratiA, 2006.Randomized trial of paclitaxeland sirolimus-eluting stents in small coronary vessels,Eur Heart J 27 260 -6
QianJ,ChenZ,MaJ,GeJ, 2012.Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials,Catheter Cardiovasc Interv 80 507 -13
ZhangF,DongL,GeJ, 2010.Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus,Am J Cardiol 105 64 -8
SchomigA,DibraA,WindeckerS., 2007.A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxeleluting stents in patients with coronary artery disease,J Am Coll Cardiol 50 1373 -80
StiermaierT,HeinzA,SchlomaD, 2014.Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimuseluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial),Catheter Cardiovasc Interv 83 418 -24
OtsukaM,YokoiH,MatsuyamaY., 2014.Comparison of sirolimusand paclitaxel-eluting stents in patients with moderate renal insufficiency: results from the J-DESsERT trial,Cardiovasc Revasc Med 15 323 -8
BligaardN,ThuesenL,SaunamäkiK., 2014.Similar five-year outcome with paclitaxel- and sirolimus-eluting coronary stents,Scand Cardiovasc J 48 148 -55
ZhangY,ShenJ,LiZ, 2013.Two-year clinical outcomes of different drug-eluting stents with different polymer coating strategies in coronary artery heart disease: A multi-centre, randomised, controlled clinical trial,Int J Cardiol 168 2646 -52
KingL,ByrneRA,MehilliJ,SchömigA,KastratiA,PacheJ, 2013.Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial,Catheter Cardiovasc Interv 81 E23 -28
JangSJ,ParkDW,KimWJ, 2013.Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial,Catheter Cardiovasc Interv 81 1106 -14
GurmHS,BoydenT,WelchKB, 2008.Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: a meta-analysis,Am Heart J 155 630 -9
ZhangX,XieJ,LiG,ChenQ,XuB, 2014.Head-to-head comparison of sirolimus-eluting stents versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of 76 studies,PLoS One 9 e97934 -
NasuK,OikawaY,Yoshikawa R, 2013.A randomized comparison of sirolimus- vs. paclitaxel-eluting stents for treatment of bifurcation lesions by single stent and kissing balloon: results of the SINGLE KISS trial,Int J Cardiol 166 187 -92
AbizaidA,OrmistonJA,FajadetJ, 2013.Two-year follow-up of the NEVO Res Elution-I(NEVO RES-I) trial: A randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions,EuroIntervention 9 721 -9
PattersonC,MaperaS,LiHH, 2006.Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling,Arterioscler Thromb Vasc Biol 26 1473 -80
SmithEJ,RothmanMT, 2003.Antiproliferative coatings for the treatment of coronary heart disease: what are the targets and which are the tools,J Interv Cardiol 16 475 -83
RogersCD, 2005.Drug-eluting stents: clinical perspectives on drug and design differences,Rev Cardiovasc Med 6 S3 -12
KastratiA,DibraA,EberleS, 2005.Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials,JAMA 294 819 -25
LeeSW,ParkSW,KimYH, 2011.A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial,Cardiovasc Interv 4 310 -16
KamoiD,IshiiH,Takahashi H. Sirolimus, 2013.- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients,Int J Cardiol 165 533 -6
KimYH,ParkSW,Lee SW, 2006.Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease,Circulation 114 2148 -53
NakazawaG,FinnAV,JonerM., 2008.Delayed arterial healing and increased late stent thrombosis at culprit sites after drugeluting stent placement for acute myocardial infarction patients: an autopsy study,Circulation 118 1138 -45
KukrejaN,OnumaY,Garcia-GarciaH,DaemenJ,van DomburgR,SerruysPW, .Primary percutaneous coronary, -
BrodieB,PokharelY,FleishmanN., 2011.Very late stent thrombosis after primary percutaneous coronary intervention with baremetal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience,JACC Cardiovasc Interv 4 30 -8
ByrneRA,IijimaR,MehilliJ, 2009.Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer,JACC Cardiovasc Interv 2 291 -9
WallaceEL,Abdel-LatifA,CharnigoR, 2012.Meta-analysis of longterm outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for STsegment elevation myocardial infarction,Am J Cardiol 109 932 -40
0

Citations

0

Downloads

164

Views